Abstract
Endocrine therapy is a required element of the management of premenopausal women with early-stage steroid hormone receptor-positive breast cancer. There is uncertainty about how best to implement that therapy using the strategies of tamoxifen and estrogen deprivation as well as how to integrate these approaches with chemotherapy. Other research focuses on identification of improved markers for endocrine response or resistance and on the special side effects of endocrine therapy in young women.
Original language | English (US) |
---|---|
Pages (from-to) | 657-663 |
Number of pages | 7 |
Journal | Seminars in oncology |
Volume | 33 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2006 |
Externally published | Yes |
ASJC Scopus subject areas
- Hematology
- Oncology